Kidney Week

Abstract: TH-OR082

Finerenone in CKD and Type 1 Diabetes

Session Information

• Opening Plenary: ASN President's Address, State-of-the-Art Lecture, Featured High-Impact Clinical Trials
  November 06, 2025 | Location: Hall A, Convention Center
  Abstract Time: 08:50 AM - 09:02 AM

Category: Diabetic Kidney Disease

• 702 Diabetic Kidney Disease: Clinical

Authors

• Heerspink, Hiddo Jan L., Rijksuniversiteit Groningen, Groningen, GR, Netherlands

Hiddo Jan L. Heerspink, PhD

• Cherney, David, University Health Network and Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada

David Cherney, MD, PhD

• Rossing, Peter, Steno Diabetes Center Copenhagen, Herlev, Capital Region of Denmark, Denmark

Peter Rossing, MD, DrMed

• Lawatscheck, Robert, Bayer AG, Berlin, Germany

Robert Lawatscheck, MD

• McGill, Janet B., Washington University in St Louis, St. Louis, Missouri, United States

Janet B. McGill, MD, MA

Group or Team Name

• On behalf of the FINE-ONE Investigators.

Background

Type 1 diabetes (T1D) is predicted to affect nearly 15 million people by 2040, and ~30% of those will develop chronic kidney disease (CKD). Although innovation in therapies to treat CKD in type 2 diabetes (T2D) has advanced in recent years, the treatment of CKD in T1D remains an area of urgent unmet need due to high residual risk. The nonsteroidal mineralocorticoid receptor antagonist finerenone has demonstrated reductions in the risk of major clinical kidney and cardiovascular outcomes in patients with CKD and T2D. Reduction in urinary albumin-creatinine ratio (UACR) explained 84% of the benefit of finerenone on the risk of a composite kidney outcome. The FINE-ONE trial (NCT05901831) assesses the efficacy and safety of finerenone in patients with CKD and T1D and uses change in UACR as a bridging biomarker to translate evidence of the long-term kidney benefits of finerenone from T2D to T1D.

Methods

FINE-ONE is a global, phase 3, double-blind trial evaluating finerenone in patients with CKD (UACR ≥200–<5000 mg/g; estimated glomerular filtration rate [eGFR] ≥25–<90 mL/min/1.73 m²), T1D, HbA1c <10%, and serum [K⁺] ≤4.8 mmol/L. Patients receiving stable renin-angiotensin system therapy were randomized 1:1 to finerenone (10 or 20 mg od) or placebo. The primary efficacy outcome was change in UACR from baseline over 6 months. Safety outcomes included the proportion of participants who experienced treatment-emergent adverse events and hyperkalemia.

Results

FINE-ONE randomized 242 patients with CKD and T1D. At baseline, the mean (standard deviation [SD]) age of patients was 52 (14) years, and 65.3% were male. The median (Q1–Q3) UACR was 549 (299–1191) mg/g, and the mean (SD) eGFR was 59 (19) mL/min/1.73 m². Mean (SD) serum [K⁺] at baseline was 4.6 (0.4) mmol/L, and mean diabetes duration was 32 years. As of 23 August 2025, all patients had completed the 6-month treatment period. The study close-out procedures and statistical analyses are ongoing. Efficacy and safety outcome results will be presented at ASN Kidney Week.

Conclusion

The FINE-ONE trial analysis will provide vital evidence for the efficacy and safety of finerenone in patients with CKD and T1D, and may result in finerenone becoming the first regulatory approved treatment for CKD associated with T1D in 30 years.

Funding

• Commercial Support – Bayer AG

Digital Object Identifier (DOI)

• doi: 10.1681/ASN.2025y0p1zsmv